|
| 36343387 | Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death. | Mol Cancer Ther | 2023 |
| 37801516 | TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinoma. | Sci Immunol | 2023 |
| 37712140 | Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types. | Clin Cancer Res | 2023 |
| 37550477 | Experimental and spontaneous metastasis assays can result in divergence in clonal architecture. | Commun Biol | 2023 |
| 37788331 | Intestinal-specific <i>Hdac3</i> deletion increases susceptibility to colitis and small intestinal tumor development in mice fed a high-fat diet. | Am J Physiol Gastrointest Liver Physiol | 2023 |
| 37148543 | Induction of endoplasmic reticulum stress is associated with the anti-tumor activity of monepantel across cancer types. | Cancer Med | 2023 |
| 36786724 | In colon cancer cells fascin1 regulates adherens junction remodeling. | FASEB J | 2023 |
| 36765160 | Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. | Sci Rep | 2023 |
| 35075138 | VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. | Sci Rep | 2022 |
| 35606410 | Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. | Cell Death Differ | 2022 |
| 35501832 | Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. | BMC Cancer | 2022 |
| 35512531 | IL-36G promotes cancer-cell intrinsic hallmarks in human gastric cancer cells. | Cytokine | 2022 |
| 36387154 | Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. | Front Oncol | 2022 |
| 34050131 | A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. | Cell Death Discov | 2021 |
| 33767439 | CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation. | Oncogene | 2021 |
| 33514526 | Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study. | Clin Cancer Res | 2021 |
| 33563752 | Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. | Mol Cancer Ther | 2021 |
| 33892786 | Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis. | Clin Epigenetics | 2021 |
| 34131107 | Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Cell Death Discov | 2021 |
| 34180969 | EHF is essential for epidermal and colonic epithelial homeostasis, and suppresses Apc-initiated colonic tumorigenesis. | Development | 2021 |
| 31471586 | Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. | Mod Pathol | 2020 |
| 33298868 | BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Cell Death Discov | 2020 |
| 32535104 | Molecular regulators of lipid metabolism in the intestine - Underestimated therapeutic targets for obesity? | Biochem Pharmacol | 2020 |
| 32314873 | Prostate cancer cell-intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. | EMBO Rep | 2020 |
| 31565185 | Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. | Oncotarget | 2019 |
| 31757939 | Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity. | Nat Commun | 2019 |
| 31731200 | Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. | iScience | 2019 |
| 29206819 | Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. | Br J Cancer | 2018 |
| 30200227 | ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer. | Molecules | 2018 |
| 30247524 | The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. | Ann Oncol | 2018 |
| 30562958 | Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles. | Pharmaceutics | 2018 |
| 29527009 | Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. | Br J Cancer | 2018 |
| 29379130 | DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. | Sci Rep | 2018 |
| 29463593 | Interleukin 33 Signaling Restrains Sporadic Colon Cancer in an Interferon-γ-Dependent Manner. | Cancer Immunol Res | 2018 |
| 29589298 | Cell Line Models of Molecular Subtypes of Colorectal Cancer. | Methods Mol Biol | 2018 |
| 28544747 | K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. | Mol Oncol | 2017 |
| 28262839 | Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. | Sci Rep | 2017 |
| 28958388 | Aberrant DNA Methylation in Colorectal Cancer: What Should We Target? | Trends Cancer | 2017 |
| 29088766 | Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. | Oncotarget | 2017 |
| 28625833 | Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity. | Gastroenterology | 2017 |
| 28611196 | ATF3 Repression of BCL-X<sub>L</sub> Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types. | Clin Cancer Res | 2017 |
| 28659148 | PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation. | Mol Cancer | 2017 |
| 26983878 | Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. | Mol Cancer Ther | 2016 |
| 26658611 | By moonlighting in the nucleus, villin regulates epithelial plasticity. | Mol Biol Cell | 2016 |
| 26496946 | Colorectal cancer atlas: An integrative resource for genomic and proteomic annotations from colorectal cancer cell lines and tissues. | Nucleic Acids Res | 2016 |
| 24632621 | PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. | Oncogene | 2015 |
| 26125443 | Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. | Br J Cancer | 2015 |
| 26092983 | The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner. | J Biol Chem | 2015 |
| 25921073 | FunRich: An open access standalone functional enrichment and interaction network analysis tool. | Proteomics | 2015 |
| 25944804 | Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. | Clin Cancer Res | 2015 |